Vistagen Therapeutics’ experimental anxiety disorder drug, fasedienol, did not achieve a statistically significant improvement over placebo in a late-stage trial. The trial enrolled 238 adults with social anxiety disorder.
Trial Results
The company reported no meaningful difference between fasedienol and placebo on key secondary measures in the overall trial population. However, a post-hoc analysis showed fasedienol improved symptoms in 123 patients with very severe social anxiety disorder.
Social anxiety disorder is a mental health condition affecting more than 30 million U.S. adults, marked by intense fear and distress in social or performance situations. Vistagen plans to shift its focus from treating short-term anxiety symptoms to broader treatment of social anxiety disorder over time.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
